Milsaperidone (VHX-896) vs Paliperidone palmitate (Invega Sustenna)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline

Milsaperidone (VHX-896)

Marketed by Vanda Pharmaceuticals

Approved in Schizophreniasmall molecule
Weak signal

NCT06494397 · Phase 1 · completed

Every participant in this trial received both VHX-896 and iloperidone, just in a different order, so there is no separate group that shows what happens without VHX-896, and nobody was blinded to which drug was being given at each stage. The trial measured drug levels in the blood to compare the two products, not any change in psychiatric symptoms, and results have not been posted yet.

No aligned efficacy figure on record for this race.

Paliperidone palmitate (Invega Sustenna)

Marketed by Johnson & Johnson

Approved in Schizophreniasmall molecule (palmitate ester prodrug, long-acting injectable suspension)
Partial signal

NCT00101634 · Phase 3 · completed

The study was randomized and double-blind, with 518 participants and a placebo comparison, and used a clinical symptom measure (change in total PANSS score) as its primary endpoint.

Next expected readout: December 2026 · NCT07493551 (registry estimate)

Reported efficacy

Part-2 (Disease Progression): Time to First Treatment Failure (From Day 1 up to 9 Months); Part 3 (Extended Disease Progression [EDP]): Change From Baseline in Cognition as Measured by the MATRICS Consensus Cognitive Battery (MCCB) Composite Score (Baseline and 18 Months); Part 3 (Disease Modification): Change From Baseline in Cognition as Measured by the MATRICS Consensus Cognitive Battery (MCCB) Composite Score (Baseline and Day 260): Treatment failure in Part II (9 months): paliperidone palmitate 29.5% vs oral antipsychotics 24.8%, P=0.377; extended 18-month analysis 28.6% vs 44.4%, P=0.080 (DREaM, Schizophr Res 2022). (missed)

Result source: NCT02431702

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointMilsaperidone (VHX-896)Paliperidone palmitate (Invega Sustenna)
PANSS total, change—Not reported-13.2 vs -2.9−10.3 vs placebo150 mg eq. · wk 13 · n 160NCT00590577
16 other results
  • -11.6 vs -2.9 100 mg eq. · wk 13 · n 161 · Phase 3 · primary NCT00590577
  • -8 vs -2.9 25 mg eq. · wk 13 · n 155 · Phase 3 · primary NCT00590577
  • -18.6 vs -17.9 wk 13 · n 389 · Phase 3 · primary NCT00589914
  • -25.5 vs -24.6 wk 104 · n 352 · Phase 3 · secondary NCT01081769
  • -24.3 vs -23.7 wk 91 · n 352 · Phase 3 · secondary NCT01081769
  • -23.5 vs -22.8 wk 78 · n 352 · Phase 3 · secondary NCT01081769
  • -21.7 vs -21.9 wk 65 · n 352 · Phase 3 · secondary NCT01081769
  • -1.8 vs -1.6 wk 52 · n 473 · Phase 3 · secondary NCT03345342
  • -21.8 vs -21.2 wk 52 · n 352 · Phase 3 · secondary NCT01081769
  • -19.5 vs -20.1 wk 39 · n 352 · Phase 3 · secondary NCT01081769
  • -18.5 vs -18.6 wk 26 · n 352 · Phase 3 · secondary NCT01081769
  • -16.2 vs -16.8 wk 17.33 · n 352 · Phase 3 · secondary NCT01081769
  • -14.5 vs -15 wk 13 · n 352 · Phase 3 · secondary NCT01081769
  • -12.2 vs -12.3 wk 8.67 · n 352 · Phase 3 · secondary NCT01081769
  • -9.4 vs -8.8 wk 4.33 · n 352 · Phase 3 · secondary NCT01081769
  • -4.8 vs -3.7 wk 1.14 · n 352 · Phase 3 · secondary NCT01081769
CGI-S, change—Not reported-1 vs 0−1 vs placebo150 mg eq. · wk 13 · n 160NCT00590577
19 other results
  • -1 vs 0 100 mg eq. · wk 13 · n 161 · Phase 3 · secondary NCT00590577
  • -1 vs 0 25 mg eq. · wk 13 · n 155 · Phase 3 · secondary NCT00590577
  • -1.1 vs -1.1 wk 104 · n 352 · Phase 3 · secondary NCT01081769
  • -1 vs -1.1 wk 91 · n 352 · Phase 3 · secondary NCT01081769
  • -1 vs -1 wk 78 · n 352 · Phase 3 · secondary NCT01081769
  • -0.9 vs -1 wk 65 · n 352 · Phase 3 · secondary NCT01081769
  • 0 vs 0 wk 52 · n 475 · Phase 3 · secondary NCT03345342
  • -1 vs -1 wk 52 · n 352 · Phase 3 · secondary NCT01081769
  • -0.9 vs -0.9 wk 39 · n 352 · Phase 3 · secondary NCT01081769
  • -0.8 vs -0.8 wk 26 · n 352 · Phase 3 · secondary NCT01081769
  • -0.7 vs -0.8 wk 17.33 · n 352 · Phase 3 · secondary NCT01081769
  • -0.6 vs -0.6 wk 13 · n 352 · Phase 3 · secondary NCT01081769
  • -0.9 vs -0.9 wk 13 · n 453 · Phase 3 · secondary NCT00589914
  • -0.4 vs -0.5 wk 8.67 · n 352 · Phase 3 · secondary NCT01081769
  • -0.3 vs -0.3 wk 4.33 · n 352 · Phase 3 · secondary NCT01081769
  • -0.1 vs -0.1 wk 1.14 · n 352 · Phase 3 · secondary NCT01081769
  • -0.2 vs -0.3 n 52 · Phase 3 · secondary NCT02431702
  • -0.7 vs -0.7 n 49 · Phase 3 · secondary NCT02431702
  • -0.5 vs -0.4 wk 65 · n 219 · Phase 4 · secondary NCT01157351
PANSS response—Not reported—Not posted · NCT00101634
PSP, change—Not reported8.3 vs 1.7+6.6 vs placebo150 mg eq. · wk 13 · n 160NCT00590577
16 other results
  • 6.1 vs 1.7 100 mg eq. · wk 13 · n 161 · Phase 3 · secondary NCT00590577
  • 2.9 vs 1.7 25 mg eq. · wk 13 · n 155 · Phase 3 · secondary NCT00590577
  • 15.2 vs 14.6 wk 104 · n 352 · Phase 3 · secondary NCT01081769
  • 14.7 vs 14 wk 91 · n 352 · Phase 3 · secondary NCT01081769
  • 14 vs 13.3 wk 78 · n 352 · Phase 3 · secondary NCT01081769
  • 12.9 vs 12.9 wk 65 · n 352 · Phase 3 · secondary NCT01081769
  • 1 vs 1.1 wk 52 · n 473 · Phase 3 · secondary NCT03345342
  • 12.7 vs 12.3 wk 52 · n 352 · Phase 3 · secondary NCT01081769
  • 11.4 vs 11.9 wk 39 · n 352 · Phase 3 · secondary NCT01081769
  • 9.9 vs 10.8 wk 26 · n 352 · Phase 3 · secondary NCT01081769
  • 7.6 vs 7.7 wk 13 · n 352 · Phase 3 · secondary NCT01081769
  • 8.5 vs 8.8 wk 13 · n 448 · Phase 3 · secondary NCT00589914
  • 4.9 vs 4.3 wk 4.33 · n 352 · Phase 3 · secondary NCT01081769
  • 7.5 vs 7 wk 78.2 · n 41 · Phase 3 · secondary NCT02431702
  • 2.5 vs 2.9 wk 39.1 · n 51 · Phase 3 · secondary NCT02431702
  • 5.8 vs 5.4 wk 65 · n 203 · Phase 4 · secondary NCT01157351
Relapse (% of patients)—Not reported—Not posted · NCT00101634

PANSS total, change

Milsaperidone (VHX-896)
—Not reported
Paliperidone palmitate (Invega Sustenna)
-13.2 vs -2.9−10.3 vs placebo150 mg eq. · wk 13 · n 160NCT00590577
16 other results
  • -11.6 vs -2.9 100 mg eq. · wk 13 · n 161 · Phase 3 · primary NCT00590577
  • -8 vs -2.9 25 mg eq. · wk 13 · n 155 · Phase 3 · primary NCT00590577
  • -18.6 vs -17.9 wk 13 · n 389 · Phase 3 · primary NCT00589914
  • -25.5 vs -24.6 wk 104 · n 352 · Phase 3 · secondary NCT01081769
  • -24.3 vs -23.7 wk 91 · n 352 · Phase 3 · secondary NCT01081769
  • -23.5 vs -22.8 wk 78 · n 352 · Phase 3 · secondary NCT01081769
  • -21.7 vs -21.9 wk 65 · n 352 · Phase 3 · secondary NCT01081769
  • -1.8 vs -1.6 wk 52 · n 473 · Phase 3 · secondary NCT03345342
  • -21.8 vs -21.2 wk 52 · n 352 · Phase 3 · secondary NCT01081769
  • -19.5 vs -20.1 wk 39 · n 352 · Phase 3 · secondary NCT01081769
  • -18.5 vs -18.6 wk 26 · n 352 · Phase 3 · secondary NCT01081769
  • -16.2 vs -16.8 wk 17.33 · n 352 · Phase 3 · secondary NCT01081769
  • -14.5 vs -15 wk 13 · n 352 · Phase 3 · secondary NCT01081769
  • -12.2 vs -12.3 wk 8.67 · n 352 · Phase 3 · secondary NCT01081769
  • -9.4 vs -8.8 wk 4.33 · n 352 · Phase 3 · secondary NCT01081769
  • -4.8 vs -3.7 wk 1.14 · n 352 · Phase 3 · secondary NCT01081769

CGI-S, change

Milsaperidone (VHX-896)
—Not reported
Paliperidone palmitate (Invega Sustenna)
-1 vs 0−1 vs placebo150 mg eq. · wk 13 · n 160NCT00590577
19 other results
  • -1 vs 0 100 mg eq. · wk 13 · n 161 · Phase 3 · secondary NCT00590577
  • -1 vs 0 25 mg eq. · wk 13 · n 155 · Phase 3 · secondary NCT00590577
  • -1.1 vs -1.1 wk 104 · n 352 · Phase 3 · secondary NCT01081769
  • -1 vs -1.1 wk 91 · n 352 · Phase 3 · secondary NCT01081769
  • -1 vs -1 wk 78 · n 352 · Phase 3 · secondary NCT01081769
  • -0.9 vs -1 wk 65 · n 352 · Phase 3 · secondary NCT01081769
  • 0 vs 0 wk 52 · n 475 · Phase 3 · secondary NCT03345342
  • -1 vs -1 wk 52 · n 352 · Phase 3 · secondary NCT01081769
  • -0.9 vs -0.9 wk 39 · n 352 · Phase 3 · secondary NCT01081769
  • -0.8 vs -0.8 wk 26 · n 352 · Phase 3 · secondary NCT01081769
  • -0.7 vs -0.8 wk 17.33 · n 352 · Phase 3 · secondary NCT01081769
  • -0.6 vs -0.6 wk 13 · n 352 · Phase 3 · secondary NCT01081769
  • -0.9 vs -0.9 wk 13 · n 453 · Phase 3 · secondary NCT00589914
  • -0.4 vs -0.5 wk 8.67 · n 352 · Phase 3 · secondary NCT01081769
  • -0.3 vs -0.3 wk 4.33 · n 352 · Phase 3 · secondary NCT01081769
  • -0.1 vs -0.1 wk 1.14 · n 352 · Phase 3 · secondary NCT01081769
  • -0.2 vs -0.3 n 52 · Phase 3 · secondary NCT02431702
  • -0.7 vs -0.7 n 49 · Phase 3 · secondary NCT02431702
  • -0.5 vs -0.4 wk 65 · n 219 · Phase 4 · secondary NCT01157351

PANSS response

Milsaperidone (VHX-896)
—Not reported
Paliperidone palmitate (Invega Sustenna)
—Not posted · NCT00101634

PSP, change

Milsaperidone (VHX-896)
—Not reported
Paliperidone palmitate (Invega Sustenna)
8.3 vs 1.7+6.6 vs placebo150 mg eq. · wk 13 · n 160NCT00590577
16 other results
  • 6.1 vs 1.7 100 mg eq. · wk 13 · n 161 · Phase 3 · secondary NCT00590577
  • 2.9 vs 1.7 25 mg eq. · wk 13 · n 155 · Phase 3 · secondary NCT00590577
  • 15.2 vs 14.6 wk 104 · n 352 · Phase 3 · secondary NCT01081769
  • 14.7 vs 14 wk 91 · n 352 · Phase 3 · secondary NCT01081769
  • 14 vs 13.3 wk 78 · n 352 · Phase 3 · secondary NCT01081769
  • 12.9 vs 12.9 wk 65 · n 352 · Phase 3 · secondary NCT01081769
  • 1 vs 1.1 wk 52 · n 473 · Phase 3 · secondary NCT03345342
  • 12.7 vs 12.3 wk 52 · n 352 · Phase 3 · secondary NCT01081769
  • 11.4 vs 11.9 wk 39 · n 352 · Phase 3 · secondary NCT01081769
  • 9.9 vs 10.8 wk 26 · n 352 · Phase 3 · secondary NCT01081769
  • 7.6 vs 7.7 wk 13 · n 352 · Phase 3 · secondary NCT01081769
  • 8.5 vs 8.8 wk 13 · n 448 · Phase 3 · secondary NCT00589914
  • 4.9 vs 4.3 wk 4.33 · n 352 · Phase 3 · secondary NCT01081769
  • 7.5 vs 7 wk 78.2 · n 41 · Phase 3 · secondary NCT02431702
  • 2.5 vs 2.9 wk 39.1 · n 51 · Phase 3 · secondary NCT02431702
  • 5.8 vs 5.4 wk 65 · n 203 · Phase 4 · secondary NCT01157351

Relapse (% of patients)

Milsaperidone (VHX-896)
—Not reported
Paliperidone palmitate (Invega Sustenna)
—Not posted · NCT00101634
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Milsaperidone (VHX-896): no structured comparison results are available for Schizophrenia.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Milsaperidone (VHX-896): 0 of 4 rows · Paliperidone palmitate (Invega Sustenna): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricPaliperidone palmitate (Invega Sustenna)
Dropout rate
—Part 2-Paliperidone Palmitate (PP)a
NCT02431702 · Phase 3
show 16 more results
—Part 3- OAP to PP (or Delayed-Star
NCT02431702 · Phase 3
—Part 3-PP to PP (Extended Disease
NCT02431702 · Phase 3
59.6%
NCT01157351 · Phase 4 · registry result, not featured evidence
—Double-blind PP6M
NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3
—Follow-up Phase PP6M
NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3
6.4%
NCT01081769 · Phase 3 · registry result, not featured evidence
40.3%Paliperidone Palmitate (Double-bli
NCT01299389 · Phase 3 · registry result, not featured evidence
—Paliperidone Palmitate (Post-0bser
NCT01299389 · Phase 3 · registry result, not featured evidence
24.8%
NCT00589914 · Phase 3 · registry result, not featured evidence
44.8%150 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
46.1%100 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
48.1%25 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
0%150 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
28.6%100 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
21.4%150/ 50 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
14.3%50 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—Part 2-Paliperidone Palmitate (PP)a
NCT02431702 · Phase 3
show 16 more results
—Part 3- OAP to PP (or Delayed-Star
NCT02431702 · Phase 3
—Part 3-PP to PP (Extended Disease
NCT02431702 · Phase 3
2.2%
NCT01157351 · Phase 4 · registry result, not featured evidence
—Double-blind PP6M
NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3
—Follow-up Phase PP6M
NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3
—
NCT01081769 · Phase 3 · registry result, not featured evidence
17%Paliperidone Palmitate (Double-bli
NCT01299389 · Phase 3 · registry result, not featured evidence
—Paliperidone Palmitate (Post-0bser
NCT01299389 · Phase 3 · registry result, not featured evidence
3.1%
NCT00589914 · Phase 3 · registry result, not featured evidence
8%150 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
6.1%100 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
6.3%25 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
0%150 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
7.1%100 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
7.1%150/ 50 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
7.1%50 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
Serious AEs
12.8%Part 2-Paliperidone Palmitate (PP)a
NCT02431702 · Phase 3
show 16 more results
5.3%Part 3- OAP to PP (or Delayed-Star
NCT02431702 · Phase 3
2%Part 3-PP to PP (Extended Disease
NCT02431702 · Phase 3
18.6%
NCT01157351 · Phase 4 · registry result, not featured evidence
5%Double-blind PP6M
NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3
5.5%Follow-up Phase PP6M
NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3
11.2%
NCT01081769 · Phase 3 · registry result, not featured evidence
6.3%Paliperidone Palmitate (Double-bli
NCT01299389 · Phase 3 · registry result, not featured evidence
3.9%Paliperidone Palmitate (Post-0bser
NCT01299389 · Phase 3 · registry result, not featured evidence
6.8%
NCT00589914 · Phase 3 · registry result, not featured evidence
—150 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
—100 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
—25 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
14.3%150 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
0%100 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
21.4%150/ 50 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
7.1%50 mg
NCT01606254 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
weight increased 28.2%
akathisia 9%
headache 9%
NCT02431702 · Phase 3
show 16 more results
weight increased 15.8%
anxiety 10.5%
insomnia 10.5%
NCT02431702 · Phase 3
weight increased 14.3%
insomnia 10.2%
nasopharyngitis 6.1%
NCT02431702 · Phase 3
injection site pain 18.6%
insomnia 18.6%
weight increased 13.3%
NCT01157351 · Phase 4 · registry result, not featured evidence
weight increased 8.4%
injection site pain 7.7%
headache 6.7%
NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3
nasopharyngitis 3.7%
upper respiratory tract infection 0.9%
headache 0%
NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3
weight increased 15.4%
insomnia 11.2%
headache 10.6%
NCT01081769 · Phase 3 · registry result, not featured evidence
insomnia 17% (placebo 15.2%)
injection site pain 13.2% (placebo 6.7%)
nasopharyngitis 12.6% (placebo 6.1%)
NCT01299389 · Phase 3 · registry result, not featured evidence
nasopharyngitis 8.4% (placebo 6.1%)
constipation 5.2% (placebo 5.5%)
insomnia 3.9% (placebo 15.2%)
NCT01299389 · Phase 3 · registry result, not featured evidence
insomnia 9.4%
headache 7.1%
somnolence 5.6%
NCT00589914 · Phase 3 · registry result, not featured evidence
150 mg eq.
injection site pain 8% (placebo 3.7%)
headache 6.1% (placebo 7.3%)
akathisia 5.5% (placebo 4.9%)
NCT00590577 · Phase 3 · registry result, not featured evidence
100 mg eq.
headache 6.7% (placebo 7.3%)
injection site pain 6.1% (placebo 3.7%)
akathisia 4.8% (placebo 4.9%)
NCT00590577 · Phase 3 · registry result, not featured evidence
25 mg eq.
headache 10.6% (placebo 7.3%)
injection site pain 8.8% (placebo 3.7%)
akathisia 1.3% (placebo 4.9%)
NCT00590577 · Phase 3 · registry result, not featured evidence
150 mg
blood prolactin increased 92.9%
insomnia 28.6%
nasopharyngitis 28.6%
NCT01606254 · Phase 2 · registry result, not featured evidence
100 mg
blood prolactin increased 64.3%
psychiatric symptom 42.9%
nasopharyngitis 28.6%
NCT01606254 · Phase 2 · registry result, not featured evidence
150/ 50 mg
blood prolactin increased 71.4%
nasopharyngitis 28.6%
alanine aminotransferase increased 21.4%
NCT01606254 · Phase 2 · registry result, not featured evidence
50 mg
blood prolactin increased 78.6%
nasopharyngitis 35.7%
psychiatric symptom 35.7%
NCT01606254 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 15 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Paliperidone palmitate (Invega Sustenna)

Time to Treatment Failure NA vs NA Oral Antipsychotics months
time to event · months
NCT02431702 · Phase 3
show 2 more results
NA vs NA Oral Antipsychotics months
NCT02431702 · Phase 3
13.67 vs 7.43 Oral Antipsychotics months*
NCT01157351 · Phase 4 · registry result, not featured evidence · converted to months from 416 days as posted
MCCB Composite 1.6 vs 3.2 Oral Antipsychotics T-score @ 78.2wk
absolute change · T-score
NCT02431702 · Phase 3
show 3 more results
-0.7 vs 0.5 Oral Antipsychotics T-score @ 37.14wk
NCT02431702 · Phase 3
-0.2 vs 0.5 Oral Antipsychotics T-score @ 37.14wk
NCT02431702 · Phase 3
2 vs 2.8 Oral Antipsychotics T-score @ 39.1wk
NCT02431702 · Phase 3
PSP 8.3 vs 1.7 placebo score @ 13wk150 mg eq.
absolute change · score
NCT00590577 · Phase 3 · registry result, not featured evidence
show 16 more results
6.1 vs 1.7 placebo score @ 13wk100 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
2.9 vs 1.7 placebo score @ 13wk25 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
2.5 vs 2.9 Oral Antipsychotics score @ 39.1wk
NCT02431702 · Phase 3
7.5 vs 7 Oral Antipsychotics score @ 78.2wk
NCT02431702 · Phase 3
5.75 vs 5.36 Oral Antipsychotics score @ 65wk
NCT01157351 · Phase 4 · registry result, not featured evidence
1 vs 1.1 PP3M score @ 52wk
NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3
4.9 vs 4.3 Oral Antipsychotics score @ 4.33wk
NCT01081769 · Phase 3 · registry result, not featured evidence
7.6 vs 7.7 Oral Antipsychotics score @ 13wk
NCT01081769 · Phase 3 · registry result, not featured evidence
9.9 vs 10.8 Oral Antipsychotics score @ 26wk
NCT01081769 · Phase 3 · registry result, not featured evidence
11.4 vs 11.9 Oral Antipsychotics score @ 39wk
NCT01081769 · Phase 3 · registry result, not featured evidence
12.7 vs 12.3 Oral Antipsychotics score @ 52wk
NCT01081769 · Phase 3 · registry result, not featured evidence
12.9 vs 12.9 Oral Antipsychotics score @ 65wk
NCT01081769 · Phase 3 · registry result, not featured evidence
14 vs 13.3 Oral Antipsychotics score @ 78wk
NCT01081769 · Phase 3 · registry result, not featured evidence
14.7 vs 14 Oral Antipsychotics score @ 91wk
NCT01081769 · Phase 3 · registry result, not featured evidence
15.2 vs 14.6 Oral Antipsychotics score @ 104wk
NCT01081769 · Phase 3 · registry result, not featured evidence
8.5 vs 8.8 RISPERDAL CONSTA score @ 13wk
NCT00589914 · Phase 3 · registry result, not featured evidence
MCCB Working Memory -0.2 vs -0.8 Oral Antipsychotics T-score @ 37.14wk
absolute change · T-score
NCT02431702 · Phase 3
show 1 more result
-1.7 vs 0.7 Oral Antipsychotics T-score @ 78.2wk
NCT02431702 · Phase 3
MCCB Verbal Learning 1.3 vs 1 Oral Antipsychotics T-score @ 37.14wk
absolute change · T-score
NCT02431702 · Phase 3
show 1 more result
0.3 vs 0.8 Oral Antipsychotics T-score @ 78.2wk
NCT02431702 · Phase 3
MCCB Speed of Processing 1.8 vs 3.5 Oral Antipsychotics T-score @ 37.14wk
absolute change · T-score
NCT02431702 · Phase 3
show 1 more result
2.5 vs 4.9 Oral Antipsychotics T-score @ 78.2wk
NCT02431702 · Phase 3
MCCB Attention/Vigilance 3.2 vs 0.7 Oral Antipsychotics T-score @ 37.14wk
absolute change · T-score
NCT02431702 · Phase 3
show 1 more result
2.4 vs 0.7 Oral Antipsychotics T-score @ 78.2wk
NCT02431702 · Phase 3
MCCB Visual Learning 1.3 vs 1.4 Oral Antipsychotics T-score @ 37.14wk
absolute change · T-score
NCT02431702 · Phase 3
show 1 more result
0.2 vs -0.2 Oral Antipsychotics T-score @ 78.2wk
NCT02431702 · Phase 3
MCCB Reasoning Problem Solving 0.2 vs 2.8 Oral Antipsychotics T-score @ 37.14wk
absolute change · T-score
NCT02431702 · Phase 3
show 1 more result
3.4 vs 4.7 Oral Antipsychotics T-score @ 78.2wk
NCT02431702 · Phase 3
MCCB Social Cognition 0.3 vs 1.6 Oral Antipsychotics T-score @ 37.14wk
absolute change · T-score
NCT02431702 · Phase 3
show 1 more result
-0.2 vs 1.4 Oral Antipsychotics T-score @ 78.2wk
NCT02431702 · Phase 3
CGI-S -1 vs 0 placebo score @ 13wk150 mg eq.
absolute change · score
NCT00590577 · Phase 3 · registry result, not featured evidence
show 19 more results
-1 vs 0 placebo score @ 13wk100 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
-1 vs 0 placebo score @ 13wk25 mg eq.
NCT00590577 · Phase 3 · registry result, not featured evidence
-0.2 vs -0.3 Oral Antipsychotics score
NCT02431702 · Phase 3
-0.7 vs -0.7 Oral Antipsychotics score
NCT02431702 · Phase 3
-0.48 vs -0.43 Oral Antipsychotics score @ 65wk
NCT01157351 · Phase 4 · registry result, not featured evidence
0 vs 0 PP3M score @ 52wk
NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3
-0.1 vs -0.1 Oral Antipsychotics score @ 1.14wk
NCT01081769 · Phase 3 · registry result, not featured evidence
-0.3 vs -0.3 Oral Antipsychotics score @ 4.33wk
NCT01081769 · Phase 3 · registry result, not featured evidence
-0.4 vs -0.5 Oral Antipsychotics score @ 8.67wk
NCT01081769 · Phase 3 · registry result, not featured evidence
-0.6 vs -0.6 Oral Antipsychotics score @ 13wk
NCT01081769 · Phase 3 · registry result, not featured evidence
-0.7 vs -0.8 Oral Antipsychotics score @ 17.33wk
NCT01081769 · Phase 3 · registry result, not featured evidence
-0.8 vs -0.8 Oral Antipsychotics score @ 26wk
NCT01081769 · Phase 3 · registry result, not featured evidence
-0.9 vs -0.9 Oral Antipsychotics score @ 39wk
NCT01081769 · Phase 3 · registry result, not featured evidence
-1 vs -1 Oral Antipsychotics score @ 52wk
NCT01081769 · Phase 3 · registry result, not featured evidence
-0.9 vs -1 Oral Antipsychotics score @ 65wk
NCT01081769 · Phase 3 · registry result, not featured evidence
-1 vs -1 Oral Antipsychotics score @ 78wk
NCT01081769 · Phase 3 · registry result, not featured evidence
-1 vs -1.1 Oral Antipsychotics score @ 91wk
NCT01081769 · Phase 3 · registry result, not featured evidence
-1.1 vs -1.1 Oral Antipsychotics score @ 104wk
NCT01081769 · Phase 3 · registry result, not featured evidence
-0.9 vs -0.9 RISPERDAL CONSTA score @ 13wk
NCT00589914 · Phase 3 · registry result, not featured evidence
Time to First Psychiatric Hospitalization or Arrest/Incarceration NA vs 9 Oral Antipsychotics months
time to event · months
NCT01157351 · Phase 4 · registry result, not featured evidence

+ 19 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Milsaperidone (VHX-896)'s landscape · Paliperidone palmitate (Invega Sustenna)'s landscape